In the first year since launching its RSV Maternal and Infant Protection Program in February 2025, Australia has achieved something remarkable: nearly half of all respiratory syncytial virus hospitalizations in newborns have simply vanished.
This is significant because RSV has long been a ruthless threat to infants. Before this program, roughly one in fifty children required hospitalization for RSV in their first year of life, and nearly all infants were infected by age three. The virus causes severe bronchiolitis and pneumonia—conditions that can be life-threatening in the youngest, most vulnerable patients. Each respiratory season, it fills pediatric hospital beds and places enormous strain on families and healthcare systems alike. Until now, treatment options once infection took hold were limited. Prevention, therefore, was the missing piece.
The new approach is elegantly two-pronged. Pregnant women across Australia received free maternal RSV vaccination under the National Immunization Program. Newborns who missed this protection in the womb became eligible for nirsevimab, a monoclonal antibody delivered through state and territory-funded programs. Both tools work.
A major national study conducted by The Kids Research Institute Australia, the National Center for Immunization Research and Surveillance (NCIRS), and Monash University—drawing data from 13 hospitals across the country through the Pediatric Active Enhanced Disease Surveillance network—found RSV-associated hospitalizations fell by 43.8% in babies aged less than three months, the group at highest risk of severe disease. That single statistic masks the human reality beneath it: far fewer tiny infants in oxygen masks, far fewer frightened parents in hospital corridors at 3 a.m.
The granular numbers reveal the power of each intervention. Babies born to mothers who received the vaccine were 80% less likely to be hospitalized with RSV. Those who received nirsevimab directly were 90% less likely. Even babies born between October 2024 and mid-February 2025—a catch-up cohort who received the monoclonal antibody—showed 87% lower risk of hospitalization.
Dr. Ushma Wadia, lead researcher and clinician-scientist at the Wesfarmers Center of Vaccines and Infectious Diseases at The Kids, and a pediatrician at Perth Children's Hospital, framed the results in their broader context. "These findings represent the first real-world evidence from the southern hemisphere demonstrating the effectiveness of a hybrid RSV prevention strategy on a national scale," she said. The work vindicates two decades of research, modeling, and collaboration among researchers determined to shield babies from this infection.
Professor Nick Wood, Associate Director of NCIRS, noted that this 44% reduction in hospitalizations in babies up to three months of age matters far beyond the statistics. It ensures pediatric hospital beds and resources remain available for those who need them most—a ripple effect that strengthens entire healthcare systems.
Surveillance through the surveillance network continues, and researchers are already asking the next questions: How long does protection last? How will the program perform across multiple RSV seasons? These ongoing studies will refine understanding and help protect future cohorts. For now, though, Australia's newborns have gained something their predecessors did not: a genuinely effective shield against a virus that once seemed inevitable.